Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Enzyme replacement therapy (ERT) with alpha-galactosidase A (alpha-Gal A) is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease. However, ERT has limitations of a short half-life, requirement for frequent administration, and limited efficacy for patients with renal failure. Therefore, we investigated the efficacy of recombinant adeno-associated virus (rAAV) vector-mediated gene therapy for a Fabry disease mouse model and compared it with that of ERT.
Methods: A pseudotyped rAAV2/8 vector encoding alpha-Gal A cDNA (rAAV2/8-hAGA) was prepared and injected into 18-week-old male Fabry mice through the tail vein. The alpha-Gal A expression level and globotriaosylceramide (Gb3) levels in the Fabry mice were examined and compared with Fabry mice with ERT. Immunohistochemical and ultrastructural studies were conducted.
Results: Treatment of Fabry mice with rAAV2/8-hAGA resulted in the clearance of accumulated Gb3 in tissues such as liver, spleen, kidney, heart, and brain with concomitant elevation of alpha-Gal A enzyme activity. Enzyme activity was elevated for up to 60 weeks. In addition, expression of the alpha-Gal A protein was identified in the presence of rAAV2/8-hAGA at 6, 12, and 24 weeks after treatment. alpha-Gal A activity was significantly higher in the mice treated with rAAV2/8-hAGA than in Fabry mice that received ERT. Along with higher alpha-Gal A activity in the kidney of the Fabry mice treated with gene therapy, immunohistochemical studies showed more alpha-Gal A expression in the proximal tubules and glomerulus, and less Gb3 deposition in Fabry mice treated with this gene therapy than in mice given ERT. The alpha-gal A gene transfer significantly reduced the accumulation of Gb3 in the tubules and podocytes of the kidney. Electron microscopic analysis of the kidneys of Fabry mice also showed that gene therapy was more effective than ERT.
Conclusions: The rAAV2/8-hAGA mediated alpha-Gal A gene therapy provided improved efficiency over ERT in the Fabry disease mouse model. Furthermore, rAAV2/8-hAGA-mediated expression showed a greater effect in the kidney than ERT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861641 | PMC |
| http://dx.doi.org/10.1186/1423-0127-17-26 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In vivo imaging of dorsal root ganglia in the mouse: from ex vivo MR-microscopy towards quantitative in vivo MRI.
Brain Res
August 2025
Institute for Diagnostic and Interventional Neuroradiology, University Hospital Würzburg, Würzburg, Germany.
Dorsal root ganglia (DRG) of the peripheral nervous system (PNS) transmit information from inside and outside the body to the central nervous system (CNS). The DRG's unique multicellular unit of neurons, endothelial cells, satellite glial and immune cells undergoes remarkable changes after nerve injury and in neuropathic pain conditions and is a target for local and systemic pain therapies. DRG-magnetic resonance imaging (DRG-MRI) visualizes structural DRG injury in various neuropathic pain syndromes and has become a promising tool for detection and monitoring of DRG-pathology in humans.
View Article and Find Full Text PDFComparative Evaluation of AAV8 and AAV9 Gene Therapy in Fabry Knockout () and Symptomatic (G3S) Murine Models.
Genes (Basel)
June 2025
Institute of Clinical Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
Background: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the GLA gene, resulting in α-galactosidase A (α-Gal A) deficiency and progressive accumulation of globotriaosylceramide (Gb3). Current therapies, such as enzyme replacement and chaperone therapy, have limitations, including incomplete biodistribution and mutation-specific efficacy. Gene therapy using adeno-associated virus (AAV) vectors presents a promising alternative.
View Article and Find Full Text PDFASIC1a-associated mechanical hypersensitivity in the GlaKO Fabry disease mouse model.
Neurobiol Pain
June 2025
Insituto de Fisiología Biología Molecular y Neurociencias-IFIBYNE-UBA-CONICET, LFBM, Argentina.
Different lines of evidence point to a role for Acid-sensing ion channel 1 (ASIC1) in pain perception, acting as sensors in both the central nervous system and peripheral tissues. While elevated ASIC1 protein expression has been documented in various pain conditions, our study focuses on its involvement in the context of Fabry disease (FD). Using a mouse model of FD, we observed a significant increase in ASIC1 protein expression in pain-related areas including the anterior cingulate cortex (ACC), as well as the spinal cord (SC) and dorsal root ganglia (DRG) at the lumbar, thoracic, and cervical levels.
View Article and Find Full Text PDFCompetent expression of effective and long-acting human α-Gal A-Fc fusion protein in the milk of transgenic mice.
Transgenic Res
July 2025
China National Biotec Group Company Ltd, Chengdu Institute of Biological Products Co., Ltd., Chengdu, 610023, Sichuan, People's Republic of China.
Fabry disease is a rare X-linked inherited lysosomal storage disorder caused by a reduction or deficiency in the activity of α-galactosidase A (α-Gal A). The short half-life of α-Gal A necessitates biweekly infusions, thereby imposing significant economic and physical burdens on patients and their families. In this study, a novel long-acting replacement for α-Gal A, termed α-galactosidase A-Fc (α-Gal A-Fc), was designed.
View Article and Find Full Text PDFPerineural immune environment of olfactory nerves is reshaped by neuroinflammatory drainage and connects to ethmoid bone marrow.
Sci Adv
June 2025
Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA.
Cerebrospinal fluid (CSF) contains inflammatory cues that enable peripheral immune surveillance of the central nervous system (CNS). While some cranial nerves allow for CSF efflux, the immune environment around CSF-interfacing cranial nerves during neuroinflammation is still poorly understood. Using a mouse model of multiple sclerosis [experimental autoimmune encephalomyelitis (EAE)] and CNS infection (CNS-Mtb), we examined immune responses around olfactory nerve bundles near the cribriform plate, a key CSF efflux route.
View Article and Find Full Text PDF